Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-5]
• Eravacycline demonstrated similar clinical outcomes and microbiologic eradication compared to carbapenems in patients with complicated intra-abdominal infection (cIAI) and concurrent bacteremia, indicating its effectiveness in this high-risk subgroup.
• In meta-analyses, cefepime plus metronidazole was shown to be more effective than tigecycline and ceftolozane/tazobactam for cIAI, making it an optimal regimen for clinical success.
• Eravacycline was associated with a higher incidence of total adverse events and nausea compared to other antibiotics, but it had fewer discontinuations due to adverse events compared to tigecycline, suggesting a more favorable safety profile in terms of tolerability.
• Eravacycline was associated with significantly greater odds of total adverse events and nausea compared to other antibiotics, although there were no significant differences in serious adverse events or discontinuation rates due to adverse events.
• In patients with cIAI and concurrent bacteremia, eravacycline demonstrated similar safety profiles to carbapenems, indicating no increased safety concerns for this high-risk population.